Market Overview

Global Non-Alcoholic Steatohepatitis (NASH) Market 2018-2025: Analysis by Drug Type and Sales Channel -- A $1.17 Billion Market in 2017, Growing to $21.47 Billion by 2025 -


The "Non-Alcoholic
Steatohepatitis (NASH) Market by Drug Type, and Sales Channel - Global
Opportunity Analysis and Industry Forecast, 2021-2025"
has been added to's offering.

The global non-alcoholic steatohepatitis (NASH) market was valued at
$1,179 million in 2017, and is expected to reach $21,478 million by
2025, growing at a CAGR of 58.4% from 2021 to 2025.

NASH is projected to lead the cause of liver transplantation in the U.S.
in the coming years. Some major factors such as higher prevalence of
NASH, expected launch of pipeline drugs, and higher number of unmet
needs drive the growth of this market. However, poor diagnosis of NASH
due to the lack of ideal diagnostic technologies limit the growth of the
NASH market.

Based on drug type, the market is segmented into vitamin E &
pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc.
Vitamin E & pioglitazone segment contributes majorly due to
effectiveness in a treatment of steatosis, inflammation, hepatocyte
ballooning, and scarring in NASH patients.

Key Findings

  • Based on drug type, the selonsertib & cenicriviroc segment is expected
    to exhibit the fastest market growth, is projected to grow at a CAGR
    of 73.7% from 2021 to 2025.
  • Based on sales channel, the retail pharmacy segment held more than
    half of the global market share in 2017 and is expected to remain
    dominant throughout the forecast period.
  • Based on sales channel, the online provider segment exhibited fastest
    growth and is anticipated to grow at a CAGR of 63.2% from 2021-2025.
  • Based on region, Asia-Pacific is expected to experience growth at the
    highest rate, registering a CAGR of 62.62% during the forecast period.

Key Topics Covered

Chapter 1: Introduction

Chapter 2: Executive Summary

Chapter 3: Market Overview

Chapter 4: Nonalcoholic Steatohepatitis (NASH) Market, by Drug Type

Chapter 5: Nonalcoholic Steatohepatitis (NASH) Market, by Sales Channel

Chapter 6: Nonalcoholic Steatohepatitis (NASH) Market, by Region

Chapter 7: Company Profiles

  • Allergan PLC
  • Cadila Healthcare Ltd.
  • Conatus Pharmaceuticals Inc.
  • Galmed Pharmaceuticals Ltd.
  • Gemphire Therapeutics Inc.
  • Genfit SA
  • Gilead Sciences Inc.
  • Intercept Pharmaceuticals Inc.
  • Novartis International AG
  • Shire PLC

For more information about this report visit

View Comments and Join the Discussion!